

# Gavin Yamey

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6410565/publications.pdf>

Version: 2024-02-01

58  
papers

2,636  
citations

411340

20  
h-index

232693

48  
g-index

59  
all docs

59  
docs citations

59  
times ranked

5025  
citing authors

#	ARTICLE	IF	CITATIONS
1	Can medical product development be better aligned with global needs?. <i>BMJ, The</i> , 2022, 376, o316.	3.0	0
2	It is not too late to achieve global covid-19 vaccine equity. <i>BMJ, The</i> , 2022, 376, e070650.	3.0	62
3	Unethical studies of ivermectin for covid-19. <i>BMJ, The</i> , 2022, 377, o917.	3.0	9
4	Scaling up community-based health insurance in Ethiopia: a qualitative study of the benefits and challenges. <i>BMC Health Services Research</i> , 2022, 22, 473.	0.9	8
5	Investing in late-stage clinical trials and manufacturing of product candidates for five major infectious diseases: a modelling study of the benefits and costs of investment in three middle-income countries. <i>The Lancet Global Health</i> , 2022, 10, e1045-e1052.	2.9	7
6	Transitioning from donor aid for health: perspectives of national stakeholders in Ghana. <i>BMJ Global Health</i> , 2021, 6, e003896.	2.0	12
7	Rich countries should tithe their vaccines. <i>Nature</i> , 2021, 590, 529-529.	13.7	20
8	Developing vaccines for neglected and emerging infectious diseases. <i>BMJ, The</i> , 2021, 372, n373.	3.0	3
9	Using the COVID-19 pandemic to reimagine global health teaching in high-income countries. <i>BMJ Global Health</i> , 2021, 6, e005649.	2.0	21
10	The covid-19 vaccine patent waiver: a crucial step towards a "people's vaccine". <i>BMJ, The</i> , 2021, 373, n1249.	3.0	27
11	Progress in the face of cuts: a qualitative Nigerian case study of maintaining progress towards universal health coverage after losing donor assistance. <i>Health Policy and Planning</i> , 2021, 36, 1045-1057.	1.0	7
12	Preparing for the next pandemic. <i>BMJ, The</i> , 2021, 373, n1295.	3.0	14
13	Achieving global mortality reduction targets and universal health coverage: The impact of COVID-19. <i>PLoS Medicine</i> , 2021, 18, e1003675.	3.9	8
14	Is the cure really worse than the disease? The health impacts of lockdowns during COVID-19. <i>BMJ Global Health</i> , 2021, 6, e006653.	2.0	51
15	Preventing pandemics in the world's most vulnerable settings. <i>BMJ, The</i> , 2021, 375, n2897.	3.0	2
16	The impact of COVID-19 on HIV financing in Nigeria: a call for proactive measures. <i>BMJ Global Health</i> , 2020, 5, e002718.	2.0	30
17	Ensuring global access to COVID-19 vaccines. <i>Lancet, The</i> , 2020, 395, 1405-1406.	6.3	240
18	Incentivising wealthy nations to participate in the COVID-19 Vaccine Global Access Facility (COVAX): a game theory perspective. <i>BMJ Global Health</i> , 2020, 5, e003627.	2.0	50

#	ARTICLE	IF	CITATIONS
19	Building a global policy agenda to prioritize preterm birth: A qualitative analysis on factors shaping global health policymaking. <i>Gates Open Research</i> , 2020, 4, 65.	2.0	7
20	Middle-income countries graduating from health aid: Transforming daunting challenges into smooth transitions. <i>PLoS Medicine</i> , 2019, 16, e1002837.	3.9	13
21	Trends in global health financing. <i>BMJ: British Medical Journal</i> , 2019, 365, l2185.	2.4	19
22	Building a tuberculosis-free world: The Lancet Commission on tuberculosis. <i>Lancet, The</i> , 2019, 393, 1331-1384.	6.3	257
23	Improving resource mobilisation for global health R&D: a role for coordination platforms?. <i>BMJ Global Health</i> , 2019, 4, e001209.	2.0	8
24	Financing Global Common Goods for Health: When the World is a Country. <i>Health Systems and Reform</i> , 2019, 5, 334-349.	0.6	31
25	Current situation and progress toward the 2030 health-related Sustainable Development Goals in China: A systematic analysis. <i>PLoS Medicine</i> , 2019, 16, e1002975.	3.9	46
26	International Funding for Global Common Goods for Health: An Analysis Using the Creditor Reporting System and G-FINDER Databases. <i>Health Systems and Reform</i> , 2019, 5, 350-365.	0.6	16
27	A quantitative analysis of sources of changes in government expenditures on health, 2000 to 2015: what can we learn from experience to date?. <i>Gates Open Research</i> , 2019, 3, 5.	2.0	1
28	Pipeline analysis of a vaccine candidate portfolio for diseases of poverty using the Portfolio-To-Impact modelling tool. <i>F1000Research</i> , 2019, 8, 1066.	0.8	3
29	A quantitative analysis of sources of changes in government expenditures on health, 2000 to 2015: what can we learn from experience to date?. <i>Gates Open Research</i> , 2019, 3, 5.	2.0	3
30	Aid Effectiveness in the Sustainable Development Goals Era Comment on "It's About the Idea Hitting the Bull's Eye": How Aid Effectiveness Can Catalyse the Scale-up of Health Innovations". <i>International Journal of Health Policy and Management</i> , 2019, 8, 184-186.	0.5	13
31	How many child deaths can be averted in Nigeria? Assessing state-level prospects of achieving 2030 sustainable development goals for neonatal and under-five mortality. <i>Gates Open Research</i> , 2019, 3, 1460.	2.0	4
32	Pipeline analysis of a vaccine candidate portfolio for diseases of poverty using the Portfolio-To-Impact modelling tool. <i>F1000Research</i> , 2019, 8, 1066.	0.8	2
33	Funding innovation in neglected diseases. <i>BMJ: British Medical Journal</i> , 2018, 360, k1182.	2.4	13
34	How many lives are at stake? Assessing 2030 sustainable development goal trajectories for maternal and child health. <i>BMJ: British Medical Journal</i> , 2018, 360, k373.	2.4	43
35	The extricable links between health, wealth, and profits. <i>BMJ: British Medical Journal</i> , 2018, 363, k4418.	2.4	5
36	Improving tracking of aid for women's, children's, and adolescents' health. <i>The Lancet Global Health</i> , 2018, 6, e814-e815.	2.9	4

#	ARTICLE	IF	CITATIONS
37	Valuing health as development: going beyond gross domestic product. <i>BMJ: British Medical Journal</i> , 2018, 363, k4371.	2.4	12
38	Alma-Ata at 40 years: reflections from the Lancet Commission on Investing in Health. <i>Lancet, The</i> , 2018, 392, 1434-1460.	6.3	71
39	Funding global health product R&D: the Portfolio-To-Impact Model (P2I), a new tool for modelling the impact of different research portfolios. <i>Gates Open Research</i> , 2018, 2, 24.	2.0	18
40	Developing new health technologies for neglected diseases: a pipeline portfolio review and cost model. <i>Gates Open Research</i> , 2018, 2, 23.	2.0	20
41	Financing of international collective action for epidemic and pandemic preparedness. <i>The Lancet Global Health</i> , 2017, 5, e742-e744.	2.9	44
42	Investing in Health Innovation: A Cornerstone to Achieving Global Health Convergence. <i>PLoS Biology</i> , 2016, 14, e1002389.	2.6	7
43	Reducing the global burden of Preterm Birth through knowledge transfer and exchange: a research agenda for engaging effectively with policymakers. <i>Reproductive Health</i> , 2016, 13, 26.	1.2	13
44	Implementing pro-poor universal health coverage. <i>The Lancet Global Health</i> , 2016, 4, e14-e16.	2.9	32
45	Prioritizing Surgical Care on National Health Agendas: A Qualitative Case Study of Papua New Guinea, Uganda, and Sierra Leone. <i>PLoS Medicine</i> , 2016, 13, e1002023.	3.9	22
46	How much donor financing for health is channelled to global versus country-specific aid functions?. <i>Lancet, The</i> , 2015, 386, 2436-2441.	6.3	40
47	Tracking global expenditures on surgery: gaps in knowledge hinder progress. <i>The Lancet Global Health</i> , 2015, 3, S2-S4.	2.9	23
48	The men's health gap: men must be included in the global health equity agenda. <i>Bulletin of the World Health Organization</i> , 2014, 92, 618-620.	1.5	165
49	Annual rates of decline in child, maternal, HIV, and tuberculosis mortality across 109 countries of low and middle income from 1990 to 2013: an assessment of the feasibility of post-2015 goals. <i>The Lancet Global Health</i> , 2014, 2, e698-e709.	2.9	34
50	Global health 2035: a world converging within a generation. <i>Lancet, The</i> , 2013, 382, 1898-1955.	6.3	976
51	Evidence-based policymaking in global health - the payoffs and pitfalls. <i>Evidence-Based Medicine</i> , 2011, 16, 97-99.	0.6	26
52	Transitioning from Health Aid: A Scoping Review of Transition Readiness Assessment Tools. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
53	Analysis of the health product pipeline for poverty-related and neglected diseases using the Portfolio-to-Impact (P2I) modeling tool. <i>F1000Research</i> , 0, 9, 416.	0.8	5
54	Developing new health technologies for neglected diseases: a pipeline portfolio review and cost model. <i>Gates Open Research</i> , 0, 2, 23.	2.0	24

#	ARTICLE	IF	CITATIONS
55	Developing new health technologies for neglected diseases: a pipeline portfolio review and cost model. <i>Gates Open Research</i> , 0, 2, 23.	2.0	12
56	Transitioning from Foreign Aid: Is the Next Cohort of Graduating Countries Ready?. <i>SSRN Electronic Journal</i> , 0, , .	0.4	2
57	Funding global health product R&D: the Portfolio-To-Impact Model (P2I), a new tool for modelling the impact of different research portfolios. <i>Gates Open Research</i> , 0, 2, 24.	2.0	2
58	Measuring development assistance for health systems strengthening and health security: an analysis using the Creditor Reporting System database. <i>F1000Research</i> , 0, 9, 584.	0.8	2